Maresin 1 induces resolution of hepatic fibrosis through RORα-dependent reprogramming of resident macrophages
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Hepatic fibrosis is a progressive pathological condition characterized by chronic inflammation and excessive extracellular matrix deposition (ECM), which may progress to cirrhosis and liver failure. Although specialized pro-resolving lipid mediators have emerged as potential therapeutic agents, their role in advanced hepatic fibrosis remains incompletely defined. This study aimed to determine whether Maresin 1 (MaR1), an endogenous pro-resolving lipid mediator, promotes the resolution of hepatic fibrosis and modulates the associated inflammatory response. Hepatic fibrosis was induced in mice and rats using diethylnitrosamine (DEN). Animals were subsequently treated with MaR1 or vehicle. Histological and biochemical parameters, apoptosis and proliferation markers, and immune profiles associated with hepatic macrophages polarization were assessed. Additionally, the expression and subcellular localization of retinoic acid related orphan receptor alpha (RORα) and nuclear factor kappa B (NF-κB p65) were analysed. MaR1 treatment significantly attenuated hepatic fibrosis, reduced the ECM accumulation, and promoted restoration of liver parenchyma, accompanied by decreased hepatocellular injury and enhanced regenerative capacity. MaR1 also induced immune reprogramming, favouring anti-inflammatory and homeostatic macrophage phenotypes. These effects were associated with increased nuclear activation of RORα and modulation of NF-κB signalling pathways. These findings demonstrate that MaR1 promotes the resolution of hepatic fibrosis through macrophage polarization and modulation of the RORα/NF-κB axis. This study advances the understanding of pro-resolving mechanisms in hepatic fibrosis and positions MaR1 as a pharmacologically relevant candidate for the development of targeted antifibrotic therapies in chronic liver disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exploring the full spectrum of macrophage activation
Mosser, D. M., & Edwards, J. P. (2008) · Nature Reviews Immunology · doi:10.1038/nri2448 · Cited by 9,144 · cited 1×
“…cells exhibit marked phenotypic plasticity and can adopt a proinflammatory phenotype (M1), characterized by the production of cytokines such as tumour necrosis factor-alpha (TNF-α ) and interleukin-1 beta (IL-1 β ) (Mosser and Edwards, 2008), thereby exacerbating tissue damage and fibrogenesis.”
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Macrophage biology in development, homeostasis and disease
Wynn, T. A., Chawla, A., & Pollard, J. W. (2013) · Nature · doi:10.1038/nature12034 · Cited by 4,684 · cited 1×
“In contrast, MoMas are recruited from the bone marrow (BM) in response to chemoattractants and, once in the parenchyma, can engage in proinflammatory or reparative functions, depending on the microenvironment (Wynn et al., 2013) .”
Macrophages in Tissue Repair, Regeneration, and Fibrosis
Wynn, T. A., & Vannella, K. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.02.015 · Cited by 4,481 · cited 1×
“Macrophages are pivotal regulators of liver injury, fibrogenesis, and tissue repair (Wynn and Vannella, 2016).”
Yunna, C., Mengru, H., Lei, W., & Weidong, C. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173090 · Cited by 2,454
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024 · cited 1×
“This regression involves a series of mechanisms such as modulation of the inflammatory microenvironment, degradation of the ECM, reduction of oxidative stress and regeneration of hepatocytes (Arthur, 2001; Caligiuri et al., 2021; Kisseleva and Brenner, 2020).”
Liver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780 · cited 1×
“It is characterized by an excessive scarring response that develops following sustained hepatic injury and chronic inflammation, leading to the accumulation of extracellular matrix (ECM) and distortion of liver architecture (Friedman, 2003).”
InfluentialLiver Macrophages in Tissue Homeostasis and Disease
Krenkel, O., & Tacke, F. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.11 · Cited by 1,424 · cited 1×
“The dynamic balance between these macrophage activation states is therefore critical for determining of whether liver injury progresses toward fibrosis or undergoes resolution (Krenkel and Tacke, 2017).”
Jetten, A. M. (2009) · Nuclear Receptor Signaling · doi:10.1621/nrs.07003 · Cited by 673 · cited 2×
“Accordingly, it is reasonable to propose that MaR1 exerts part of its immunomodulatory and metabolic effects through ROR α activation (Jetten, 2009).”
M1/M2 macrophages and their overlaps – myth or reality?
Strizova, Z., Benesova, I., Bartolini, R., Novysedlak, R., Cecrdlova, E., Foley, L. K., & Striz, I. (2023) · Clinical Science · doi:10.1042/cs20220531 · Cited by 612 · cited 1×
“In fact, several studies have suggested a broader and more dynamic functional spectrum of intermediate states between M1 and M2, which are induced depending on the balance of inflammatory, metabolic, and tissue stimuli (Strizova et al., 2023).”
Research works printed but not linked: 8
- Beljaars, 2014, Hepatic localization of macrophage phenotypes during fibrogenesis and resolution of fibrosis in mice and humans, Front. Immunol., 5, 109533, 10.3389/FIMMU.2014.00430/BIBTEX · doi:10.3389/fimmu.2014.00430/bibtex
- Freedman, 2020, Biosynthesis of the maresin intermediate, 13S,14S-Epoxy-DHA, by human 15-Lipoxygenase and 12-Lipoxygenase and its regulation through negative allosteric modulators, Biochemistry, 59, 1832, 10.1021/acs.biochem.0c00233/suppl_file/bi0c00233_si_001.pdf · doi:10.1021/acs.biochem.0c00233/suppl_file/bi0c00233_si_001.pdf
- Li, 2021, Maresin 1 attenuates lipopolysaccharide-induced acute kidney Injury via inhibiting NOX4/ROS/NF-κB pathway, Front. Pharmacol., 12, 782660, 10.3389/FPHAR.2021.782660/BIBTEX · doi:10.3389/fphar.2021.782660/bibtex
- Pawlak, 2015, Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease, J. Hepatology, 62, 720, 10.1016/j.jhep.2014.10.039/asset/564df50d-33ea-4270-a683-3de59ea00476/main.assets/gr3.jpg · doi:10.1016/j.jhep.2014.10.039/asset/564df50d-33ea-4270-a683-3de59ea00476/main.assets/gr3.jpg
- Rodríguez, 2021, Maresin-1 prevents liver fibrosis by targeting Nrf2 and NF-κB, reducing oxidative stress and inflammation, Cells, 10, 3406, 10.3390/cells10123406/s1 · doi:10.3390/cells10123406/s1
- Shamsan, 2024, The role of PI3k/AKT signaling pathway in attenuating liver fibrosis: a comprehensive review, Front. Med., 11, 1389329, 10.3389/fmed.2024.1389329/pdf · doi:10.3389/fmed.2024.1389329/pdf
- Zhang, 2022, An M0 macrophage-related prognostic model for hepatocellular carcinoma, BMC Cancer, 22, 1, 10.1186/s12885-022-09872-y/figures/8 · doi:10.1186/s12885-022-09872-y/figures/8
- Zhu, 2016, Pro-resolving lipid mediators improve neuronal survival and increase Aβ42 phagocytosis, Mol. Neurobiol., 53, 2733, 10.1007/s12035-015-9544-0/figures/9 · doi:10.1007/s12035-015-9544-0/figures/9
Cited by
Endogenous Lipid Signals in Energy Homeostasis and Fibrosis
Meo, C. D., Palaniappan, S., Urbano, C., Cimino, G., Cestra, F., Dominicis, N. D., Carnicelli, V., Tisi, A., & Maccarrone, M. (2026) · Biomolecules · doi:10.3390/biom16081170
Martin, M. Q. S., Olivera-Fuentes, C., Vielma, F. H., Norambuena-González, R., Solís-Céspedes, E., González, D. R., Perera-Sardiña, Y., & Zúñiga‐Hernández, J. (2026) · Biomolecules · doi:10.3390/biom16111558
Self-citation
Metadata
- Authors
- Herrera Vielma, F., Quiñones San Martin, M., Muñoz-Carrasco, N., Berrocal-Navarrete, F., Herrada, A. A., Olate-Briones, A., Zagmutt, S., Rodríguez-Rodríguez, R., González, D. R., & Zúñiga-Hernandez, J.
- Affiliations
- Pharmacology Laboratory, Biomedical Sciences Department, Faculty of Health Sciences, University of Talca
- Universidad de Talca (CL)
- University of Concepción (CL)
- Lymphatic Vasculature and Inflammation Research Laboratory, Department of Clinical Biochemistry and Immunology, Pharmacy Faculty, Universidad de Concepción
- Universitat Internacional de Catalunya (ES)
- Basic Sciences Department, Faculty of Medicine and Health Sciences, Universitat Internacional de Catalunya
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2026-04-27
- Volume
- 17
- Pages
- 1826739-1826739
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC13158560
- OpenAlex
- W7156374301
- Cited by
- 2
- References
- 58
- Citations by year
- 2026: 2
- FWCI
- 7.96
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Keywords
- maresin 1, liver fibrosis, RORα, NF-κB signaling, hepatic macrophages, macrophage polarization, specialized pro-resolving mediators, extracellular matrix deposition, antifibrotic therapy, chronic liver disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Maresin 1 induces resolution of hepatic fibrosis through RORα-dependent reprogramming of resident macrophages. https://app.cochat.ai/papers/10.3389/fphar.2026.1826739
- The paper
- Herrera Vielma, F., Quiñones San Martin, M., Muñoz-Carrasco, N., Berrocal-Navarrete, F., Herrada, A. A., Olate-Briones, A., Zagmutt, S., Rodríguez-Rodríguez, R., González, D. R., & Zúñiga-Hernandez, J. (2026). Maresin 1 induces resolution of hepatic fibrosis through RORα-dependent reprogramming of resident macrophages. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1826739
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.